Publications

BDI along with colleagues in the field of diabetes health and mental well being are continuously working on research projects to further improve the lives of people living with diabetes worldwide.

I'm looking for information about...

Behavioral-Diabetes-Institute_Couples

For People with Diabetes

For Healthcare Professionals

Community Resources

Scales and Measures

Scales & Measures

Behavioral-Diabetes-Institute_Icons-Mental-Health

Diabetes Distress Assessment

Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial

Authors: Thomas Martens, Roy W Beck, Ryan Bailey, Katrina J Ruedy, Peter Calhoun, Anne L Peters, Rodica Pop-Busui, Athena Philis-Tsimikas, Shichun Bao, Guillermo Umpierrez, Georgia Davis, Davida Kruger, Anuj Bhargava, Laura Young, Janet B McGill, Grazia Aleppo, Quang T Nguyen, Ian Orozco, William Biggs, K Jean Lucas, William H Polonsky, John B Buse, David Price, Richard M Bergenstal, MOBILE Study

Read More »

Exploring Why People With Type 2 Diabetes Do or Do Not Persist With Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Qualitative Study

Authors: William Polonsky, Cory Gamble, Neeraj Iyer, Mona Martin, Carol Hamersky Abstract Objective: Despite the demonstrated benefits of glucagon-like peptide 1 (GLP-1) receptor agonist therapy, adherence and persistence with this therapy is often challenging. The purpose of this study was to expand current understanding of patients’ experiences, motivations, and challenges relevant to their persistence with GLP-1 receptor agonist therapy. Design

Read More »

“Hyperglycemia aversiveness”: Investigating an overlooked problem among adults with type 1 diabetes

Authors: W H Polonsky, A L Fortmann, D Price, L Fisher Abstract Aims: To investigate the problem of adults with type 1 diabetes (T1D) who purposefully keep their glucose levels low, and to explore contributors to, and possible impact of, this potentially dangerous phenomenon. Methods: We developed three self-report items as a means to identify individuals who endorse a consistent

Read More »

Insulin Metrics: Need for Development of Consensus Standards for Reporting of Insulin Dosing Data

Authors: Howard Wolpert, William H Polonsky, David Rodbard Abstract The advent of connected insulin pens will generate an avalanche of digital insulin data, especially in the context of prandial- and multiple daily injection-insulin regimens. There is a need for the diabetes community to develop standards for such data, analogous to what has been achieved using the ambulatory glucose profile and

Read More »

Overcoming psychological insulin resistance: A practical guide for healthcare professionals

Authors: Frank J Snoek, Lawrence Fisher, William H Polonsky, Heather Stuckey, Danielle Hessler, Tricia Tang, Norbert Hermanns, Xavier Mundet, Maria Silva, Jackie Sturt, Kentaro Okazaki, Irene Hadjiyianni, Urvi Desai, Magaly Perez-Nieves Abstract Despite the demonstrated benefits of using insulin, nearly a third of the patients with type 2 diabetes (T2D) are initially reluctant to initiate insulin therapy when it is

Read More »

Quality of life in patients with type 2 diabetes after switching to insulin degludec: results from a cross-sectional survey

Authors: Chioma Uzoigwe, Michael Radin, Carol M Hamersky, Mitch DeKoven, Cassie Holt, Swapna Karkare, William H Polonsky Abstract Purpose: Five quality of life (QoL) domains are particularly important to patients with type 2 diabetes (T2D) using basal insulin-sense of physical well-being, sense of safety regarding hypoglycemia, sense of diabetes as burdensome, feelings of freedom and flexibility, and sleep quality. Methods:

Read More »

The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5)

Authors: Arndís F Ólafsdóttir, Jan Bolinder, Tim Heise, William Polonsky, Magnus Ekelund, Magnus Wijkman, Aldina Pivodic, Elsa Ahlén, Erik Schwarcz, Thomas Nyström, Jarl Hellman, Irl B Hirsch, Marcus Lind Abstract Aim: To identify responders to continuous glucose monitoring (CGM) in relation to reductions in HbA1c and percentage of time spent in hypoglycaemia after initiation of CGM for individuals with type

Read More »

Tedious, Tiresome, and Dull: An Unrecognized Problem That We Can Solve

Author: William H. Polonsky Abstract Editor’s Note: This article is adapted from the virtual address Dr. Polonsky delivered as the recipient of the American Diabetes Association’s (ADA’s) Outstanding Educator in Diabetes Award for 2020. He delivered the address in June 2020 during the Association’s 80th Scientific Sessions, held online as a result of the coronavirus disease 2019. Source: https://pubmed.ncbi.nlm.nih.gov/33627999/

Read More »

Change in Hemoglobin A1c and Quality of Life with Real-Time Continuous Glucose Monitoring Use by People with Insulin-Treated Diabetes in the Landmark Study

Authors: Timothy Gilbert, Adam Noar, Olivia Blalock, William Polonsky Abstract Background: Initiating continuous glucose monitoring (CGM) can affect hemoglobin A1c (HbA1c) levels and patients’ relationship with their diabetes. We used real-world HbA1c data to quantify short-term changes in glycemia and validated psychosocial questionnaires to assess changes in quality-of-life indicators in people during their first few months of CGM use. Methods:

Read More »

Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI

Authors: Marcus Lind, Arndís F Ólafsdóttir, Irl B Hirsch, Jan Bolinder, Sofia Dahlqvist, Aldina Pivodic, Jarl Hellman, Magnus Wijkman, Erik Schwarcz, Henrik Albrektsson, Tim Heise, William Polonsky Abstract Objective: Continuous glucose monitoring (CGM) reduces HbA1c and time spent in hypoglycemia in people with type 1 diabetes (T1D) treated with multiple daily insulin injections (MDI) when evaluated over shorter time periods.

Read More »

BDI Monthly Events

March 12Case Consultation Meeting
March 12: BDI hosts the San Diego-wide, monthly case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at [email protected] if you are in the greater San Diego area and would like further information about this program.
March 19-22International Conference
18th International Conference for ATTD (Advanced Technologies and Treatments for Diabetes) in Amsterdam, Dr. Polonsky (BDI President) has three presentations.
March 19Type 2 Presentation
On March 19, Dr. Polonski will present CGM is Wonderful, But… at the Roche-sponsored symposium, “Translating the Power of Prediction into Diabetes Management”, and Insulin Therapy Experience: Considering the Needs of People Living with Diabetes (with Professor Cukierman-Yaffe) at the Sanofi-sponsored symposium, Confidence and Simplicity in Diabetes Management”. https://attd.kenes.com/
March 20Type 2 Presentation
On March 20, Dr. Polonski will present Improved Patient- and Physician-Reported Outcomes with IGlarLixi When Switching From Premixed Insulin in People with Type 2 Diabetes: The Soli-Switch Study. https://cslide.ctimeetingtech.com/attd25/attendee/confcal/session/calendar/2025-03-20

Publications

BDI along with colleagues in the field of diabetes health and mental well being are continuously working on research projects

Read More